This study demonstrated that SGLT2 inhibitors decrease liver, visceral, and subcutaneous fat mass and normalize body composition in these patients (Wei et al., 2021). SGLT2 inhibitors …

2020年5月16日 · SGLT2 inhibitors are relevant to gastroenterologists and hepatologists for 2 main reasons. First, because of their multiple metabolic benefits, SGLT2 inhibitors may be …

We found that SGLT-2 inhibitors improved the serum levels of liver enzymes, liver fat, and liver fibrosis with additional beneficial effects on various metabolic and anthropometric parameters …

3 天之前 · Moreover, randomized controlled trials have confirmed that SGLT-2 inhibitors can reduce liver enzymes levels, intrahepatic fat content and liver fibrosis markers [16, 17]. Parallel …

2022年9月21日 · The expression of SGLT2 was observed in the hepatocytes of patients with chronic liver disease. The undirected graphical model demonstrated the complex interaction of …

Sodium-glucose co-transporter type-2 (SGLT2) inhibitors have been identified to have a crucial hepatoprotective role in patients with type 2 diabetes (T2DM) and metabolic-associated …

Treatment with SGLT2 inhibitors improves liver structure and function in patients with T2D. This meta-analysis suggests that SGLT2 inhibitors are a promising pharmacological approach for …

This was inspired by the positive effects of SGLT2 inhibitors in patients with metabolic and inflammatory pathologies, such as DM2 and associated heart failure , diabetic cardiomyopathy …

2025年2月26日 · Preclinical studies have shown that SGLT2 inhibition reduces liver fat accumulation, improves liver function markers, and decreases inflammation in animal models …

5 天之前 · In the liver, FGF-21 gene expression, protein concentration and triglyceride content were evaluated. glucose plasma levels and body weight were higher in ob/ob than in lean …

2023年2月10日 · SGLT2 is the major enzyme responsible for glucose reabsorption in the kidney and its inhibition causes a reduction in the threshold for glucose loss in urine. The excess loss …

2024年1月24日 · A systematic review of four RCTs and four observational studies done by Raj et al. 44 reported favorable effects of SGLT-2 inhibitors on the level of liver enzymes, liver fat, …

2024年1月31日 · SGLT2 inhibitors have been proven useful as antidiabetic treatment in patients with metabolic liver disease, with most robust data from patients with metabolic dysfunction …

2020年10月1日 · Therapeutic inhibition of the sodium–glucose co-transporter 2 (SGLT2) leads to substantial loss of energy (in the form of glucose) and additional solutes (in the form of Na + …

Clin Gastroenterol Hepatol. 2020 Sep;18 (10):2168-2172.e2. doi: 10.1016/j.cgh.2020.05.021. Epub 2020 May 16. 1 Gastroenterology Service, Department of General Medicine, Sengkang …

Pre-clinical studies demonstrated that SGLT2-I reduce glucotoxicity and promote anti-inflammatory effects by lowering oxidative stress. To investigate the effects of SGLT2-I on …

2023年8月1日 · Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has been verified to improve Non-alcoholic fatty liver disease (NAFLD) in previous clinical practice. We mainly aim to …

2020年12月1日 · SGLT2 inhibitors could improve liver enzymes, including alanine aminotransferase, gamma-glutamyl transferase, and liver fat, in patients with T2D with …

In this review, we summarize the current understanding of the NAFLD pathophysiology, and specifically focus on the potential impact of SGLT-2i in NAFLD development and progression, …

SGLT2 inhibitors have been proven useful as antidiabetic treatment in patients with metabolic liver disease, with most robust data from patients with metabolic dysfunction-associated steatotic …